Ceribell reported > $22M Q3’25 revenue, raised FY25 revenue guidance to $87M–$89M, and received FDA 510(k) clearance for its delirium monitoring solution.
Ceribell reported > $22M Q3’25 revenue, raised FY25 revenue guidance to $87M–$89M, and received FDA 510(k) clearance for its delirium monitoring solution.